TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03774888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft at time of bone graft
Description: following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acellular Demal Matrix at time of bone graft
Description: following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No soft tissue grafting at time of bone graft
Description: Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
Study: NCT00573872

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Phase I: 20-25 Gy in 5 fractions~Phase II: 9-24 GY in 1 fraction
Study: NCT02768688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain connectivity and physiology
Description: MRI to measure glymphactic flow during simulated natural sleep and again on return to wakefulness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Administering of 0.5-1.0 mcg/kg/hr of dexmedetomidine to ensure subject's loss of consciousness.
Study: NCT03243305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMPHORA
Description: non-hormonal contraceptive vaginal gel
Study: NCT02250456

Intervention type: PROCEDURE
Intervention: Echo doppler
Description: vascular ultrasound explorations
Study: NCT02216279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PulmoBind
Description: PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PulmoBind
Description: PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
Study: NCT05030532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVERYbody Project
Description: Brief behavioral group intervention (4 hours across two meetings)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video + Expressive Writing
Description: Brief video-based group intervention (4 hours across two meetings)
Study: NCT03234803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: poly-amide
Description: new denture base material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: poly-methyl methacrylate
Description: gold standard for denture base materials
Study: NCT01211145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: 0.5 mg nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: 2.5 mg nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: 5.0 mg nasal spray
Study: NCT04004260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavior Therapy
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet-based Cognitive Behavior Therapy
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
Study: NCT01497067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF CACHET Phakic Lens (L-series)
Description: Intraocular lens for the treatment of moderate to high myopia
Study: NCT00673257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: pharmacological studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dual x-ray absorptimetry
Study: NCT01472445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT03895203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points.
Study: NCT02616445

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UE2343
Description: * UE2343~* 10mg, 20, 35mg~* twice daily for 9 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * 10mg, 20, 35mg~* twice daily for 9 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Cross-over study~* single dose administered twice (on day 1 and day 8)~* study duration 17 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UE2343
Description: * Cross-over study~* UE2343~* single dose administered twice (on day 1 and day 8)~* study duration 17 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UE2343
Description: * UE2343~* twice daily for 3 days~* single dose on day 4
Study: NCT03955159

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Description: The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic supplementation
Description: The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
Study: NCT01643447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diammonium glycyrrhizinate
Study: NCT03936153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abexinostat
Description: abexinostat tablet
Study: NCT03638960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either liposomal bupivacaine prior to the patient receiving surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either plain bupivacaine prior to the patient receiving surgery.
Study: NCT00910845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).

Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Description: Normal saline (placebo) injected into the detrusor at Day 1.
Study: NCT06478329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Core Stabilization Exercise Training
Description: The effects of 6 weeks progressive core stabilization exercise training on adolescent volleyball players' balance, strength and endurance
Study: NCT01590901

Intervention type: DRUG
Group type: OTHER
Intervention: Probucol
Description: 250mg (1 tablet) bid. p.o for 14 consecutive days
Study: NCT03948152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the sites standard of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mask Advice Tool
Description: Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the mask advice tool.
Study: NCT02191345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Guided imagery is a stress management technique that uses verbal suggestion and descriptive language to guide the listener into imagining sensations and visualizing images in the mind in order to bring about a desired physical response, such as reduction in anxiety, stress, or pain. The guided imagery tracks chosen for the study were chosen because their goal is relaxation and stress relief, and their length is under 15 minutes.
Study: NCT00512499

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention
Description: Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Intervention
Description: INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)
Study: NCT01383018

Intervention type: DEVICE
Intervention: AMS Penile Prosthesis Devices
Description: Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
Study: NCT02646319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Albumin-Bound Rapamycin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02488018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Provision of experimental honey
Description: Acacia, Becium grandiflorum, Croton macrostachys, Eucalyptus globules, Hypoestes, Leaucas abyssinica, Schefflera abyssinica, Syzygium guineense and reference glucose were used as test food.~25g available carbohydrate of the test food was provided to ten human subjects after fasted for 11 hours overnight.
Study: NCT02574364

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: The application of abdomen CT
Description: A modified incision(MI)was designed based on abdomen CT.Using a MI compare traditional incision(TI) to the patient including cut extended, operating time,cut infection, false-positive rate,rehabilitation and return to work.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional incision
Description: McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
Study: NCT03871985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subglottic secretion lavage combined with aspiration
Description: Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion lavage combined with aspiration was performed every 4 hours: Underwent preoxygenation before cuff pressure checking, and was maintained between 30 and 35 cmH2O. After aspirating secretions from the mouth, nose, and airway, 2-5 mL distilled sterile water was instilled through the subglottic lumen, and then the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat lavage and aspiration until the irrigation fluid is clear. After washing, cuff pressure checking and was maintained between 25 and 30 cmH2O.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subglottic secretion aspiration
Description: Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion aspiration was performed every 4 hours:Underwent preoxygenation before cuff pressure checking ,and was maintained between 25 and 30 cmH2O. After aspirating secretions from the mouth, nose, and airway, the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat suction until the secretion is completely absorbed.
Study: NCT02537665

Intervention type: OTHER
Group type: OTHER
Intervention: heating precondition

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: heating precondition
Study: NCT01148264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 1x10mg per day for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: 3x10mg per day for three days
Study: NCT01151969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New multicomponent 7H intervention
Description: The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
Study: NCT02853045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: period with drug (trade name) then period with generic
Description: The list of drugs is detailed in the study description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: period with generic then period with drug (trade name)
Description: The list of drugs is detailed in the study description
Study: NCT00822146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT
Description: classified
Study: NCT02423083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanabenz
Study: NCT01358786

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: quilting suture
Description: * quilting sutures and drains~* quilting sutures but no drains

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quilting suture
Description: * quilting sutures and drains~* quilting sutures but no drains

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quilting suture
Description: * quilting sutures and drains~* quilting sutures but no drains
Study: NCT04577417

Intervention type: DRUG
Intervention: ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Description: Both ADHD and control groups of subjects will participate in 2 sessions (on-med and off-med conditions) conducted on the same day. ADHD group will be asked to come to the laboratory in the morning before taking their morning ADHD stimulant medication. They will be tested before and after taking their ADHD medication (off-med and on-med conditions). The investigators will observe changes between the two conditions.
Study: NCT02195973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
Study: NCT04224532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum Timing (Before Positioning)
Description: Before Reverse Trendelenburg Position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum Timing (After Positioning)
Description: After Reverse Trendelenburg Position
Study: NCT03480594

Intervention type: DRUG
Intervention: MRI Tracer
Description: Hyperpolarized \[1-13C\] pyruvate for injection under IND133229 used to enhance MRI/MRS/MRSI using a 3T MRI scanner.

Intervention type: DRUG
Intervention: MRI Tracer
Description: Hyperpolarized \[1-13C\] pyruvate for injection under IND133229 used to enhance MRI/MRS/MRSI using a 3T MRI scanner.
Study: NCT01539746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVI without BAV
Description: Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAVI standard procedure
Description: TAVI standard procedure including BAV before valve deployment
Study: NCT01765569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
Study: NCT00650338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 ophthalmic solution, low concentration
Description: Topical ocular application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 ophthalmic solution, medium concentration
Description: Topical ocular application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 ophthalmic solution, high concentration
Description: Topical ocular application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.005% latanoprost
Description: Topical ocular application
Study: NCT02981914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
Study: NCT02401035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV pantoprazole
Description: Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight
Study: NCT02998996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg HA/strain and 1% Endocine™
Description: intranasal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg HA/strain and 2% Endocine™
Description: intranasal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg HA/strain
Description: intranasal administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intramuscular comparator
Description: intramuscular administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intranasal comparator
Description: intranasal administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Saline
Description: intranasal administration
Study: NCT02447913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher
Description: Introduction of vouchers will improve uptake of family method as well as child immunization.~Incentivizing the providers to improve their counseling skills will improve the provider client relationship and better compliance of Family planning method
Study: NCT04333212

Intervention type: DEVICE
Group type: OTHER
Intervention: DR. Chip HPV genotyping IVD kit
Description: HPV typing by gene chip
Study: NCT00921713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncology Nurse Care Management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-centered materials
Study: NCT04326387

Intervention type: DIAGNOSTIC_TEST
Intervention: SAMBA II (Diagnostic for the Real World)
Description: Point of care Isothermal-PCR Viral RNA Amplication for virus detection

Intervention type: DIAGNOSTIC_TEST
Intervention: Public Health England Gold Standard
Description: Reverse Transcription PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Cambridge Validated Viral Detection Method
Description: Reverse Transcription PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological Detection
Description: Chest X-ray \& CT Scan detection of viral infection in the lungs